Share information
231.20 €
+2.21 %
30/04/2026 17:39
+2.21 %
Open
High
Low
Volume
224.80 €
231.20 €
223.80 €
344,743
Latest News
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026
24-Apr-2026
Acquisition of own shares
17-Apr-2026
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science